Added to YB: 2026-07-15
Pitch date: 2026-07-13
LLY [neutral]
Eli Lilly and Company
-1.16%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$1.1T
Pitch Price
$1.2K
Price Target
N/A
Dividend
0.59%
EV/EBITDA
29.97
P/E
41.98
EV/Sales
15.11
Sector
Pharmaceuticals
Category
growth
Show full summary:
Eli Lilly Is Revolutionising Medicine – The Market May Already Expect Too Much
LLY (overview): Obesity/diabetes drugs (Mounjaro, Zepbound) drove rev from $22B to $65B+, EBITDA margins 31%→43%, strong FCF/ROIC recovery. But at ~56x earnings, 35x+ EBITDA, 0.7% FCF yield, valuation prices permanence. Needs ~20% profit growth/yr for a decade just for avg returns. Normalization risk.
Read full article (3 min)